YHYanan Hu

Yanan Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanan Hu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Canxia Xu

    Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China

    2 shared publications
  • Jiahui Lin

    Digestive Diseases Center, Guangdong Provincial Key Laboratory of Digestive Cancer Research, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong 518107, China

    2 shared publications
  • Sha Cheng

    Department of Gastroenterology, Third Xiangya Hospital of Central South University, Changsha 410013, China

    2 shared publications
  • Gao You

    A, RBM15B, HL-1 cell, apoptosis

    1 shared publication
  • Guowei Wang

    Center for Experimental Medicine Third Xiangya Hospital Central South University Changsha 410013 China csu.edu.cn

    1 shared publication
  • Hanmin Liu

    Department of Pediatric Pulmonology and Immunology, West China Second University Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Comprehensive Analysis of Differences in N6-Methyladenosine RNA Methylation Groups in CVB3-Induced Viral Myocarditis and Identification of the Anti-Apoptotic Role of RBM15B

    by Yanan Hu, Jiahui Lin, Lu Yi, Sha Cheng, Gao You, Huan Chang, Hanmin Liu, Zuocheng Yang, Shuyue Chen

    Background: Viral myocarditis (VMC) is a leading cause of sudden cardiac death in children and young adults, with Coxsackievirus B3 (CVB3) identified as the primary viral pathogen responsible. N6-methyladenosine (m6A), the most abundant and reversible RNA methylation modification in mammals, plays a pivotal role in regulating numerous biological processes. However, the potential effects of CVB3 infection on m6A methylation within the myocardium remain unexplored. In this study, we investigated alterations in global RNA m6A methylation levels during CVB3 infection using both in vitro and in vivo models, and further examined the regulatory role of the m6A methyltransferase RBM15B in vitro. Methods: First, the total quantity of m6A was quantified in Balb/c mice and HL-1 cells with CVB3 infection via m6A dot blot analysis. Subsequently, m6A methylation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) were performed on cell model, while RNA-seq was conducted on animal tissues. We further analyzed the expression of m6A regulatory genes and their involvement in key pathways linked to VMC pathogenesis to elucidate underlying mechanisms. Given the pronounced expression of RBM15B in vitro, we knocked down RBM15B and assessed its regulatory effects on CVB3-infected HL-1 cells using Western blotting, viral plaque assays, and Calcein AM/PI double staining. Results: Quantitative m6A analysis revealed elevated m6A modification levels in CVB3 infection group. MeRIP-seq identified 327 significantly altered m6A peaks (116 upregulated, 211 downregulated). RNA-seq detected 1,597 upregulated and 2,942 downregulated mRNAs. Integrated analysis of MeRIP-seq and RNA-seq identified 38 hypermethylated-upregulated, 23 hypermethylated-downregulated, 65 hypomethylated-downregulated, and 13 hypomethylated-upregulated genes. GO and KEGG pathway analyses of these differentially methylated genes highlighted their roles in broad biological functions. Furthermore, qRT-PCR validation of mice RNA-seq data confirmed significant differences in four key genes (Igtp, ApoI9b, Ddit3, and Irgm3), along with altered expression of m6A regulators (IGF2BP2, EIF3H, RBM15B, and YTHDC2), with RBM15B showing the most pronounced changes. RBM15B knockdown in HL-1 cells reduced CVB3 replication (viral plaque assay) and attenuated apoptosis induced by CVB3 infection (Calcein AM/PI staining and Western blotting). Conclusion: These findings establish a foundation for exploring the role of m6A methylation in CVB3-associated VMC and may provide novel therapeutic insights for managing CVB3-induced viral myocarditis.


  • Open Access

    Orphan Class A GPCRs Signature Predicts Prognosis and Immune Microenvironment in Gastric Cancer: GPR176 Drives Tumor Progression Through Wnt Signaling and Macrophage Polarization

    by Jiahui Lin, Lingling Ke, Sha Cheng, Wei Lu, Yanan Hu, Xiyi He, Tingting Luo, Yuting Liu, Canxia Xu, Jian Qi

    Background: Orphan class A G protein‐coupled receptors (GPCRs) are a large and diverse family with broad tissue expression, and their roles in tumors are increasingly recognized. However, their involvement in gastric cancer (GC) remains unclear. Methods: We performed survival and differential expression analyses to characterize orphan class A GPCR expression patterns in stomach adenocarcinoma (STAD). A prognostic risk model was developed using univariate Cox and LASSO regression analysis and validated in the GEO database. Drug sensitivity and immune infiltration were evaluated across different risk groups. The role of GPR176 in GC and its relationship with tumor immunity were further explored using cellular assays. Results: A model incorporating nine orphan class A GPCRs (GPR15, GPR150, GPR176, GPR4, GPR26, GPR78, GPR101, GPR34, and GPR87) was constructed, showing a positive correlation with M2 macrophages and naive B cells. Low‐risk patients showed higher sensitivity to AZD6482, BX.795, GDC0941, and pazopanib. GPR176 was found to be upregulated in GC, and functional assays demonstrated that its knockdown suppressed proliferation and migration in the GC cell lines SGC‐7901 and HGC‐27. GPR176 also modulated the Wnt/β‐catenin pathway and M2 macrophage polarization. Conclusion: These findings may provide new insights into the role of orphan class A GPR genes in STAD and identify GPR176 as a new therapeutic target for GC.


  • Open Access

    Pan-Cancer Analysis of the Cuproptosis-Related Gene DLD

    by Jiahui Lin, Guowei Wang, Sha Cheng, Yanan Hu, Huan Li, Wanjiang Feng, Xiaoming Liu, Canxia Xu

    Background. Cancer affects millions of people each year and imposes a huge economic and social burden worldwide. Cuproptosis is a recently discovered novel mode of cell death. The exact function of the cuproptosis-related gene dihydrolipoamide dehydrogenase (DLD) and its role in pan-cancer is unknown. Methods. Data were retrieved from the GTEx, TCGA, and multiple online websites. These data were used to assess the expression, prognosis, and diagnostic value of DLD in various tumors. The relationship of DLD with immune microenvironment immunomodulators, immune checkpoints, tumor mutational load (TMB), microsatellite instability (MSI), and oncology drug sensitivity was explored by correlation analysis. Results. The mRNA and protein expression of DLD differs in most cancers. Survival analysis showed that DLD was associated with prognosis with KIRC, KIRP, KICH, and UCS. DLD had a strong diagnostic value in KIRC, GBM, PAAD, and LGG (AUC0.9). DLD promoter methylation affects the aberrant expression of LIHC, LUSC, PAAD, READ, and THCA. DLD was negatively correlated with stromal score, immune score, and ESTIMATE score in UCEC, TGCT, LUSC, and SARC. In UCS, resting memory CD4 T cells and activated NK cells were significantly correlated with DLD expression. Significant correlations were also observed between DLD expression and immunomodulators, immune checkpoints, TMB, and MSI in various cancers. Importantly, we also identified a number of potential drugs that may target DLD. Conclusion. DLD expression is associated with a variety of tumor prognoses and plays an integral role in tumorigenesis, tumor metabolism, and immunity.